% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:834120,
      author       = {Galldiks, Norbert and Albert, Nathalie L. and Sommerauer,
                      Michael and Grosu, Anca L. and Ganswindt, Ute and Law, Ian
                      and Preusser, Matthias and Le Rhun, Emilie and Vogelbaum,
                      Michael A. and Zadeh, Gelareh and Dhermain, Fr?d?ric and
                      Weller, Michael and Langen, Karl-Josef and Tonn, J?rg C.},
      title        = {{PET} {I}maging in {P}atients with {M}eningioma - {R}eport
                      of the {RANO}/{PET} {G}roup},
      journal      = {Neuro-Oncology},
      volume       = {19},
      number       = {12},
      issn         = {1523-5866},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {FZJ-2017-04120},
      pages        = {1576–1587},
      year         = {2017},
      abstract     = {Meningiomas are the most frequent nonglial primary brain
                      tumors and represent about $30\%$ of brain tumors. Usually,
                      diagnosis and treatment planning are based on neuroimaging
                      using mainly MRI or, rarely, CT. Most common treatment
                      options are neurosurgical resection and radiotherapy (eg,
                      radiosurgery, external fractionated radiotherapy). For
                      follow-up after treatment, a structural imaging technique
                      such as MRI or CT is used. However, these structural imaging
                      modalities have limitations, particularly in terms of tumor
                      delineation as well as diagnosis of posttherapeutic reactive
                      changes. Molecular imaging techniques such as PET can
                      characterize specific metabolic and cellular features which
                      may provide clinically relevant information beyond that
                      obtained from structural MR or CT imaging alone. Currently,
                      the use of PET in meningioma patients is steadily
                      increasing. In the present article, we provide
                      recommendations for the use of PET imaging in the clinical
                      management of meningiomas based on evidence generated from
                      studies being validated by histology or clinical course.},
      cin          = {INM-3 / INM-4 / JARA-BRAIN},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406 /
                      $I:(DE-82)080010_20140620$},
      pnm          = {573 - Neuroimaging (POF3-573)},
      pid          = {G:(DE-HGF)POF3-573},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28605532},
      UT           = {WOS:000417204200010},
      doi          = {10.1093/neuonc/nox112},
      url          = {https://juser.fz-juelich.de/record/834120},
}